- Home
- EHTH vs ATAI Comparison
EHTH vs ATAI Comparison
Compare EHTH & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EHTH
- ATAI
- Stock Information
- Founded
- EHTH 1997
- ATAI 2018
- Country
- EHTH United States
- ATAI Germany
- Employees
- EHTH N/A
- ATAI N/A
- Industry
- EHTH Specialty Insurers
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- EHTH Finance
- ATAI Health Care
- Exchange
- EHTH Nasdaq
- ATAI Nasdaq
- Market Cap
- EHTH 292.7M
- ATAI 280.2M
- IPO Year
- EHTH 2006
- ATAI 2021
- Fundamental
- Price
- EHTH $10.05
- ATAI $1.99
- Analyst Decision
- EHTH Hold
- ATAI Strong Buy
- Analyst Count
- EHTH 5
- ATAI 4
- Target Price
- EHTH $7.70
- ATAI $9.00
- AVG Volume (30 Days)
- EHTH 288.4K
- ATAI 4.9M
- Earning Date
- EHTH 02-26-2025
- ATAI 03-27-2025
- Dividend Yield
- EHTH N/A
- ATAI N/A
- EPS Growth
- EHTH N/A
- ATAI N/A
- EPS
- EHTH N/A
- ATAI N/A
- Revenue
- EHTH $464,891,000.00
- ATAI $331,000.00
- Revenue This Year
- EHTH $12.92
- ATAI $80.07
- Revenue Next Year
- EHTH $5.43
- ATAI N/A
- P/E Ratio
- EHTH N/A
- ATAI N/A
- Revenue Growth
- EHTH 15.78
- ATAI N/A
- 52 Week Low
- EHTH $3.58
- ATAI $1.03
- 52 Week High
- EHTH $11.36
- ATAI $2.85
- Technical
- Relative Strength Index (RSI)
- EHTH 51.88
- ATAI 51.96
- Support Level
- EHTH $9.20
- ATAI $1.94
- Resistance Level
- EHTH $11.07
- ATAI $2.16
- Average True Range (ATR)
- EHTH 0.63
- ATAI 0.34
- MACD
- EHTH -0.04
- ATAI -0.03
- Stochastic Oscillator
- EHTH 39.35
- ATAI 48.38
About EHTH eHealth Inc.
eHealth Inc is a company involved in private health insurance marketplace with a technology and service platform that provides consumer engagement, education and health insurance enrollment solutions. The company operates its business in two segments: Medicare and Employer and Individual. It derives maximum revenue from Medicare Segment. All of the company's revenue is from the United States. It also has a presence in China.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.